


COMBIOXIN SIGNS LICENSING AGREEMENT WITH EAGLE PHARMACEUTICALS. THE ADVISORS

Posted on 2 September 2021



Category: [Deal & transactions](#)

Tags: [Christian Wyss](#), [Ex-Featured](#), [Luzius Zumstein](#), [Pauline Pfirter](#), [Vischer](#)



Combioxin, a clinical phase biotechnology company based in Epalinges, Switzerland, has signed a worldwide commercial license agreement with Eagle Pharmaceuticals, a fully integrated pharmaceutical company based in Woodcliff Lake, NY, USA.

Under the terms of the agreement, Eagle Pharmaceuticals will be solely responsible for the continued clinical development of CAL02 and will provide an upfront payment, followed by further payments upon achievement of development milestones, regulatory approval and based on commercial sales. Eagle Pharmaceutical plans to invest \$ 35 million to achieve interim results. These interim results are expected for the first half of 2023.

[Vischer](#) advised Combioxin on all legal questions in connection with the license agreement. The Vischer team was led by **Christian Wyss** (partner, corporate / m&a, pictured) with **Pauline Pfirter** (associate, corporate / m&a), and **Luzius Zumstein** (senior associate, corporate / m&a).